Loading...

Beam Therapeutics Inc.

BEAM•NASDAQ
Healthcare
Biotechnology
$27.11
$-3.05(-10.11%)
U.S. Market opens in 64h 37m

Beam Therapeutics Inc. (BEAM) Stock Overview

Explore Beam Therapeutics Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap2.8B
P/E Ratio-38.39
EPS (TTM)$-0.81
ROE-0.07%
Fundamental Analysis

AI Price Forecasts

1 Month$17.88
3 Months$20.04
1 Year Target$22.34

BEAM Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Beam Therapeutics Inc. (BEAM) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 60.02, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $22.34.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -38.39 and a market capitalization of 2.8B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-10.11%
5-Day Change
-14.32%
1-Month Change
13.19%
3-Month Change
-14.10%
6-Month Change
-3.04%
Year-to-Date (YTD) Change
-2.20%
1-Year Change
34.41%
3-Year Change
-11.14%
5-Year Change
-66.88%
All-Time (Max) Change
44.59%

Contact Information

https://www.beamtx.com
857 327 8775
238 Main Street, Cambridge, MA, 02142

Company Facts

393 Employees
IPO DateFeb 6, 2020
CountryUS
Actively Trading

Frequently Asked Questions